nodes	percent_of_prediction	percent_of_DWPC	metapath
Tiludronate—PTPN1—Regulation of IFNG signaling—SOCS1—psoriasis	0.0324	0.0614	CbGpPWpGaD
Tiludronate—Developmental delay—Acitretin—psoriasis	0.0226	0.0478	CcSEcCtD
Tiludronate—Congenital anomaly—Acitretin—psoriasis	0.0226	0.0478	CcSEcCtD
Tiludronate—ATP6V1A—Iron uptake and transport—CP—psoriasis	0.0214	0.0405	CbGpPWpGaD
Tiludronate—PTPN1—Growth hormone receptor signaling—SOCS1—psoriasis	0.021	0.0399	CbGpPWpGaD
Tiludronate—PTPN1—Regulation of IFNA signaling—SOCS1—psoriasis	0.0197	0.0374	CbGpPWpGaD
Tiludronate—PTPN1—Regulation of IFNG signaling—IFNG—psoriasis	0.0171	0.0324	CbGpPWpGaD
Tiludronate—Congenital anomaly—Mycophenolic acid—psoriasis	0.0149	0.0314	CcSEcCtD
Tiludronate—Developmental delay—Mycophenolic acid—psoriasis	0.0149	0.0314	CcSEcCtD
Tiludronate—PTPN1—Interferon alpha/beta signaling—HLA-C—psoriasis	0.0137	0.0259	CbGpPWpGaD
Tiludronate—PTPN1—Leptin signaling pathway—REL—psoriasis	0.0133	0.0251	CbGpPWpGaD
Tiludronate—PTPN1—Interferon gamma signaling—HLA-C—psoriasis	0.013	0.0247	CbGpPWpGaD
Tiludronate—Influenza-like symptoms—Acitretin—psoriasis	0.012	0.0254	CcSEcCtD
Tiludronate—Congenital anomaly—Mycophenolate mofetil—psoriasis	0.0117	0.0248	CcSEcCtD
Tiludronate—Developmental delay—Mycophenolate mofetil—psoriasis	0.0117	0.0248	CcSEcCtD
Tiludronate—PTPN1—Interferon alpha/beta signaling—HLA-E—psoriasis	0.0114	0.0215	CbGpPWpGaD
Tiludronate—PTPN1—Regulation of IFNA signaling—TYK2—psoriasis	0.0111	0.0211	CbGpPWpGaD
Tiludronate—ATP6V1A—Latent infection of Homo sapiens with Mycobacterium tuberculosis—NOS2—psoriasis	0.0109	0.0208	CbGpPWpGaD
Tiludronate—PTPN1—Interferon gamma signaling—HLA-E—psoriasis	0.0108	0.0205	CbGpPWpGaD
Tiludronate—PTPN1—Hemostasis—SERPINB8—psoriasis	0.0106	0.0201	CbGpPWpGaD
Tiludronate—PTPN1—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	0.0102	0.0194	CbGpPWpGaD
Tiludronate—Bone pain—Calcitriol—psoriasis	0.0101	0.0213	CcSEcCtD
Tiludronate—PTPN1—Interferon Signaling—DDX58—psoriasis	0.00976	0.0185	CbGpPWpGaD
Tiludronate—PTPN1—Interferon alpha/beta signaling—SOCS1—psoriasis	0.00948	0.018	CbGpPWpGaD
Tiludronate—PTPN1—Interferon gamma signaling—SOCS1—psoriasis	0.00904	0.0171	CbGpPWpGaD
Tiludronate—Bone pain—Acitretin—psoriasis	0.00897	0.019	CcSEcCtD
Tiludronate—PTPN1—Signaling events mediated by PTP1B—LEP—psoriasis	0.00836	0.0159	CbGpPWpGaD
Tiludronate—Influenza like illness—Acitretin—psoriasis	0.00835	0.0177	CcSEcCtD
Tiludronate—PTPN1—Growth hormone receptor signaling—STAT3—psoriasis	0.0083	0.0157	CbGpPWpGaD
Tiludronate—PTPN1—Interferon alpha/beta signaling—HLA-B—psoriasis	0.00809	0.0153	CbGpPWpGaD
Tiludronate—PTPN1—Interferon gamma signaling—HLA-B—psoriasis	0.00771	0.0146	CbGpPWpGaD
Tiludronate—PTPN1—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—psoriasis	0.00752	0.0143	CbGpPWpGaD
Tiludronate—PTPN1—Interferon alpha/beta signaling—HLA-A—psoriasis	0.00749	0.0142	CbGpPWpGaD
Tiludronate—Pain—Calcipotriol—psoriasis	0.00743	0.0157	CcSEcCtD
Tiludronate—PTPN1—Interferon gamma signaling—HLA-A—psoriasis	0.00714	0.0136	CbGpPWpGaD
Tiludronate—PTPN1—Interferon gamma signaling—HLA-DRB1—psoriasis	0.00653	0.0124	CbGpPWpGaD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—DDX58—psoriasis	0.00652	0.0124	CbGpPWpGaD
Tiludronate—Influenza-like symptoms—Cyclosporine—psoriasis	0.0064	0.0135	CcSEcCtD
Tiludronate—PTPN1—Signaling events mediated by PTP1B—TYK2—psoriasis	0.00638	0.0121	CbGpPWpGaD
Tiludronate—PTPN1—Interferon Signaling—HLA-C—psoriasis	0.00637	0.0121	CbGpPWpGaD
Tiludronate—PTPN1—Interferon gamma signaling—ICAM1—psoriasis	0.00627	0.0119	CbGpPWpGaD
Tiludronate—PTPN1—Leptin signaling pathway—LEP—psoriasis	0.00624	0.0118	CbGpPWpGaD
Tiludronate—PTPN1—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	0.00617	0.0117	CbGpPWpGaD
Tiludronate—Back pain—Beclomethasone—psoriasis	0.00586	0.0124	CcSEcCtD
Tiludronate—PTPN1—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	0.00574	0.0109	CbGpPWpGaD
Tiludronate—PTPN1—Signaling events mediated by TCPTP—VEGFA—psoriasis	0.00557	0.0106	CbGpPWpGaD
Tiludronate—PTPN1—Signaling events mediated by TCPTP—STAT3—psoriasis	0.00551	0.0105	CbGpPWpGaD
Tiludronate—Influenza like illness—Mycophenolic acid—psoriasis	0.00549	0.0116	CcSEcCtD
Tiludronate—Pain—Tazarotene—psoriasis	0.00548	0.0116	CcSEcCtD
Tiludronate—PTPN1—Interferon alpha/beta signaling—TYK2—psoriasis	0.00534	0.0101	CbGpPWpGaD
Tiludronate—PTPN1—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	0.00533	0.0101	CbGpPWpGaD
Tiludronate—PTPN1—Interferon Signaling—HLA-E—psoriasis	0.00529	0.01	CbGpPWpGaD
Tiludronate—PTPN1—Interferon gamma signaling—IFNG—psoriasis	0.00477	0.00904	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—KIR2DS1—psoriasis	0.00472	0.00896	CbGpPWpGaD
Tiludronate—Bone pain—Mycophenolate mofetil—psoriasis	0.00466	0.00985	CcSEcCtD
Tiludronate—Pain—Clobetasol propionate—psoriasis	0.00464	0.00982	CcSEcCtD
Tiludronate—PTPN1—Insulin Signaling—SOCS1—psoriasis	0.00461	0.00875	CbGpPWpGaD
Tiludronate—PTPN1—Signaling events mediated by PTP1B—STAT3—psoriasis	0.00447	0.00848	CbGpPWpGaD
Tiludronate—Influenza like illness—Cyclosporine—psoriasis	0.00444	0.00939	CcSEcCtD
Tiludronate—PTPN1—Interferon Signaling—SOCS1—psoriasis	0.00441	0.00837	CbGpPWpGaD
Tiludronate—Rhinitis—Acitretin—psoriasis	0.00433	0.00915	CcSEcCtD
Tiludronate—Rhinitis—Fluocinolone Acetonide—psoriasis	0.00431	0.00912	CcSEcCtD
Tiludronate—Vertigo—Methoxsalen—psoriasis	0.00426	0.009	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—HLA-C—psoriasis	0.00425	0.00807	CbGpPWpGaD
Tiludronate—Pain—Beclomethasone—psoriasis	0.00423	0.00894	CcSEcCtD
Tiludronate—Pain—Fluocinonide—psoriasis	0.00419	0.00886	CcSEcCtD
Tiludronate—PTPN1—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	0.00399	0.00757	CbGpPWpGaD
Tiludronate—PTPN1—Interferon Signaling—HLA-B—psoriasis	0.00377	0.00714	CbGpPWpGaD
Tiludronate—PTPN1—Leptin signaling pathway—NFKB1—psoriasis	0.00371	0.00704	CbGpPWpGaD
Tiludronate—PTPN1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—JUN—psoriasis	0.00366	0.00694	CbGpPWpGaD
Tiludronate—Back pain—Acitretin—psoriasis	0.00363	0.00769	CcSEcCtD
Tiludronate—Back pain—Fluocinolone Acetonide—psoriasis	0.00362	0.00766	CcSEcCtD
Tiludronate—Myalgia—Calcitriol—psoriasis	0.0036	0.0076	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—HLA-E—psoriasis	0.00353	0.00669	CbGpPWpGaD
Tiludronate—PTPN1—Interferon Signaling—HLA-A—psoriasis	0.00349	0.00662	CbGpPWpGaD
Tiludronate—Dyspepsia—Methoxsalen—psoriasis	0.0034	0.0072	CcSEcCtD
Tiludronate—Headache—Clobetasol propionate—psoriasis	0.0034	0.0072	CcSEcCtD
Tiludronate—Vertigo—Fluocinolone Acetonide—psoriasis	0.00337	0.00712	CcSEcCtD
Tiludronate—ATP6V1A—Signaling by Insulin receptor—TYK2—psoriasis	0.00336	0.00637	CbGpPWpGaD
Tiludronate—PTPN1—Leptin signaling pathway—STAT3—psoriasis	0.00333	0.00633	CbGpPWpGaD
Tiludronate—Dizziness—Beclomethasone—psoriasis	0.00327	0.00692	CcSEcCtD
Tiludronate—Dizziness—Fluocinonide—psoriasis	0.00324	0.00685	CcSEcCtD
Tiludronate—Myalgia—Acitretin—psoriasis	0.0032	0.00676	CcSEcCtD
Tiludronate—Arthralgia—Acitretin—psoriasis	0.0032	0.00676	CcSEcCtD
Tiludronate—Arthralgia—Fluocinolone Acetonide—psoriasis	0.00319	0.00675	CcSEcCtD
Tiludronate—PTPN1—Interferon Signaling—HLA-DRB1—psoriasis	0.00319	0.00605	CbGpPWpGaD
Tiludronate—Musculoskeletal discomfort—Calcitriol—psoriasis	0.00314	0.00664	CcSEcCtD
Tiludronate—Headache—Beclomethasone—psoriasis	0.0031	0.00655	CcSEcCtD
Tiludronate—PTPN1—Hemostasis—ITGAL—psoriasis	0.00308	0.00584	CbGpPWpGaD
Tiludronate—Headache—Fluocinonide—psoriasis	0.00307	0.00649	CcSEcCtD
Tiludronate—PTPN1—Interferon Signaling—ICAM1—psoriasis	0.00306	0.0058	CbGpPWpGaD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—SOCS1—psoriasis	0.00295	0.00559	CbGpPWpGaD
Tiludronate—Pain—Calcitriol—psoriasis	0.00295	0.00623	CcSEcCtD
Tiludronate—Nausea—Beclomethasone—psoriasis	0.00294	0.00621	CcSEcCtD
Tiludronate—Rhinitis—Mycophenolic acid—psoriasis	0.00285	0.00602	CcSEcCtD
Tiludronate—Gastrointestinal pain—Calcitriol—psoriasis	0.00282	0.00596	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Acitretin—psoriasis	0.00279	0.00591	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Fluocinolone Acetonide—psoriasis	0.00279	0.00589	CcSEcCtD
Tiludronate—Abdominal pain—Calcitriol—psoriasis	0.00272	0.00576	CcSEcCtD
Tiludronate—Dyspepsia—Acitretin—psoriasis	0.0027	0.00571	CcSEcCtD
Tiludronate—Pain—Acitretin—psoriasis	0.00262	0.00555	CcSEcCtD
Tiludronate—Pain—Fluocinolone Acetonide—psoriasis	0.00261	0.00553	CcSEcCtD
Tiludronate—ATP6V1A—Transmembrane transport of small molecules—CP—psoriasis	0.00257	0.00488	CbGpPWpGaD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—JUN—psoriasis	0.00256	0.00486	CbGpPWpGaD
Tiludronate—Dizziness—Methoxsalen—psoriasis	0.00256	0.00541	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—HLA-B—psoriasis	0.00251	0.00477	CbGpPWpGaD
Tiludronate—Gastrointestinal pain—Acitretin—psoriasis	0.00251	0.0053	CcSEcCtD
Tiludronate—PTPN1—Interferon Signaling—TYK2—psoriasis	0.00249	0.00472	CbGpPWpGaD
Tiludronate—Asthenia—Calcitriol—psoriasis	0.00247	0.00523	CcSEcCtD
Tiludronate—ATP6V1A—Transmembrane transport of small molecules—CARM1—psoriasis	0.00245	0.00466	CbGpPWpGaD
Tiludronate—Abdominal pain—Acitretin—psoriasis	0.00242	0.00513	CcSEcCtD
Tiludronate—Headache—Methoxsalen—psoriasis	0.00242	0.00512	CcSEcCtD
Tiludronate—PTPN1—Immune System—ERAP1—psoriasis	0.00242	0.00459	CbGpPWpGaD
Tiludronate—Back pain—Mycophenolic acid—psoriasis	0.00239	0.00505	CcSEcCtD
Tiludronate—Diarrhoea—Calcitriol—psoriasis	0.00236	0.00499	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—HLA-A—psoriasis	0.00233	0.00442	CbGpPWpGaD
Tiludronate—PTPN1—Interferon Signaling—IFNG—psoriasis	0.00233	0.00442	CbGpPWpGaD
Tiludronate—Rhinitis—Cyclosporine—psoriasis	0.0023	0.00487	CcSEcCtD
Tiludronate—Nausea—Methoxsalen—psoriasis	0.0023	0.00486	CcSEcCtD
Tiludronate—Rhinitis—Mycophenolate mofetil—psoriasis	0.00225	0.00475	CcSEcCtD
Tiludronate—Vertigo—Mycophenolic acid—psoriasis	0.00222	0.00469	CcSEcCtD
Tiludronate—PTPN1—PDGFR-beta signaling pathway—STAT3—psoriasis	0.00222	0.0042	CbGpPWpGaD
Tiludronate—Asthenia—Acitretin—psoriasis	0.0022	0.00465	CcSEcCtD
Tiludronate—PTPN1—Signaling Pathways—HCAR2—psoriasis	0.00218	0.00413	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—HCAR2—psoriasis	0.00218	0.00413	CbGpPWpGaD
Tiludronate—Headache—Calcitriol—psoriasis	0.00216	0.00457	CcSEcCtD
Tiludronate—PTPN1—Immune System—DDX58—psoriasis	0.00213	0.00404	CbGpPWpGaD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—HLA-DRB1—psoriasis	0.00213	0.00404	CbGpPWpGaD
Tiludronate—Dyspepsia—Hydroxyurea—psoriasis	0.00212	0.00448	CcSEcCtD
Tiludronate—Arthralgia—Mycophenolic acid—psoriasis	0.0021	0.00445	CcSEcCtD
Tiludronate—Myalgia—Mycophenolic acid—psoriasis	0.0021	0.00445	CcSEcCtD
Tiludronate—PTPN1—Insulin Signaling—JUN—psoriasis	0.0021	0.00399	CbGpPWpGaD
Tiludronate—Diarrhoea—Acitretin—psoriasis	0.0021	0.00444	CcSEcCtD
Tiludronate—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.00209	0.00442	CcSEcCtD
Tiludronate—Pain—Hydroxyurea—psoriasis	0.00206	0.00435	CcSEcCtD
Tiludronate—Nausea—Calcitriol—psoriasis	0.00205	0.00433	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—ICAM1—psoriasis	0.00204	0.00388	CbGpPWpGaD
Tiludronate—Dizziness—Acitretin—psoriasis	0.00203	0.00429	CcSEcCtD
Tiludronate—Dizziness—Fluocinolone Acetonide—psoriasis	0.00202	0.00428	CcSEcCtD
Tiludronate—Rhinitis—Triamcinolone—psoriasis	0.00193	0.00407	CcSEcCtD
Tiludronate—Headache—Acitretin—psoriasis	0.00192	0.00406	CcSEcCtD
Tiludronate—Headache—Fluocinolone Acetonide—psoriasis	0.00192	0.00405	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—TAGAP—psoriasis	0.00189	0.00358	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—TAGAP—psoriasis	0.00189	0.00358	CbGpPWpGaD
Tiludronate—Back pain—Mycophenolate mofetil—psoriasis	0.00189	0.00399	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	0.00184	0.00388	CcSEcCtD
Tiludronate—Nausea—Acitretin—psoriasis	0.00182	0.00385	CcSEcCtD
Tiludronate—Nausea—Fluocinolone Acetonide—psoriasis	0.00182	0.00384	CcSEcCtD
Tiludronate—Vertigo—Cyclosporine—psoriasis	0.0018	0.0038	CcSEcCtD
Tiludronate—Dyspepsia—Mycophenolic acid—psoriasis	0.00177	0.00375	CcSEcCtD
Tiludronate—Vertigo—Mycophenolate mofetil—psoriasis	0.00175	0.0037	CcSEcCtD
Tiludronate—Asthenia—Hydroxyurea—psoriasis	0.00173	0.00365	CcSEcCtD
Tiludronate—Pain—Mycophenolic acid—psoriasis	0.00172	0.00365	CcSEcCtD
Tiludronate—Arthralgia—Cyclosporine—psoriasis	0.0017	0.0036	CcSEcCtD
Tiludronate—Myalgia—Cyclosporine—psoriasis	0.0017	0.0036	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—TYK2—psoriasis	0.00166	0.00315	CbGpPWpGaD
Tiludronate—Arthralgia—Mycophenolate mofetil—psoriasis	0.00166	0.00351	CcSEcCtD
Tiludronate—Myalgia—Mycophenolate mofetil—psoriasis	0.00166	0.00351	CcSEcCtD
Tiludronate—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.00165	0.00349	CcSEcCtD
Tiludronate—Diarrhoea—Hydroxyurea—psoriasis	0.00165	0.00348	CcSEcCtD
Tiludronate—ATP6V1A—Signaling by Insulin receptor—IL6—psoriasis	0.00164	0.00312	CbGpPWpGaD
Tiludronate—Vertigo—Prednisolone—psoriasis	0.00163	0.00346	CcSEcCtD
Tiludronate—Back pain—Triamcinolone—psoriasis	0.00162	0.00342	CcSEcCtD
Tiludronate—PTPN1—Immune System—ITGAL—psoriasis	0.00161	0.00306	CbGpPWpGaD
Tiludronate—Vertigo—Hydrocortisone—psoriasis	0.0016	0.00337	CcSEcCtD
Tiludronate—Abdominal pain—Mycophenolic acid—psoriasis	0.00159	0.00337	CcSEcCtD
Tiludronate—Dizziness—Hydroxyurea—psoriasis	0.00159	0.00337	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—IFNG—psoriasis	0.00155	0.00295	CbGpPWpGaD
Tiludronate—Myalgia—Hydrocortisone—psoriasis	0.00151	0.0032	CcSEcCtD
Tiludronate—PTPN1—Immune System—REL—psoriasis	0.00151	0.00286	CbGpPWpGaD
Tiludronate—Headache—Hydroxyurea—psoriasis	0.00151	0.00319	CcSEcCtD
Tiludronate—Vertigo—Triamcinolone—psoriasis	0.0015	0.00318	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.00149	0.00314	CcSEcCtD
Tiludronate—PTPN1—Immune System—IFIH1—psoriasis	0.00147	0.00278	CbGpPWpGaD
Tiludronate—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.00145	0.00307	CcSEcCtD
Tiludronate—Asthenia—Mycophenolic acid—psoriasis	0.00145	0.00306	CcSEcCtD
Tiludronate—Dyspepsia—Cyclosporine—psoriasis	0.00144	0.00304	CcSEcCtD
Tiludronate—Nausea—Hydroxyurea—psoriasis	0.00143	0.00302	CcSEcCtD
Tiludronate—Myalgia—Triamcinolone—psoriasis	0.00142	0.00301	CcSEcCtD
Tiludronate—PTPN1—Platelet activation, signaling and aggregation—VEGFA—psoriasis	0.00142	0.00269	CbGpPWpGaD
Tiludronate—Dyspepsia—Mycophenolate mofetil—psoriasis	0.0014	0.00296	CcSEcCtD
Tiludronate—Pain—Cyclosporine—psoriasis	0.00139	0.00295	CcSEcCtD
Tiludronate—PTPN1—Immune System—HLA-C—psoriasis	0.00139	0.00263	CbGpPWpGaD
Tiludronate—Diarrhoea—Mycophenolic acid—psoriasis	0.00138	0.00292	CcSEcCtD
Tiludronate—PTPN1—Immune System—TNFAIP3—psoriasis	0.00137	0.0026	CbGpPWpGaD
Tiludronate—Vertigo—Betamethasone—psoriasis	0.00136	0.00288	CcSEcCtD
Tiludronate—Vertigo—Dexamethasone—psoriasis	0.00136	0.00288	CcSEcCtD
Tiludronate—Pain—Mycophenolate mofetil—psoriasis	0.00136	0.00288	CcSEcCtD
Tiludronate—Gastrointestinal pain—Cyclosporine—psoriasis	0.00133	0.00282	CcSEcCtD
Tiludronate—Dizziness—Mycophenolic acid—psoriasis	0.00133	0.00282	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.00132	0.00279	CcSEcCtD
Tiludronate—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.0013	0.00275	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—NFKB1—psoriasis	0.00129	0.00245	CbGpPWpGaD
Tiludronate—Myalgia—Dexamethasone—psoriasis	0.00129	0.00273	CcSEcCtD
Tiludronate—Myalgia—Betamethasone—psoriasis	0.00129	0.00273	CcSEcCtD
Tiludronate—Abdominal pain—Cyclosporine—psoriasis	0.00129	0.00273	CcSEcCtD
Tiludronate—Dyspepsia—Hydrocortisone—psoriasis	0.00128	0.0027	CcSEcCtD
Tiludronate—Pain—Prednisolone—psoriasis	0.00127	0.00268	CcSEcCtD
Tiludronate—Headache—Mycophenolic acid—psoriasis	0.00126	0.00267	CcSEcCtD
Tiludronate—PTPN1—Hemostasis—NOS2—psoriasis	0.00126	0.00239	CbGpPWpGaD
Tiludronate—Abdominal pain—Mycophenolate mofetil—psoriasis	0.00126	0.00266	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.00124	0.00263	CcSEcCtD
Tiludronate—Pain—Hydrocortisone—psoriasis	0.00124	0.00262	CcSEcCtD
Tiludronate—Dyspepsia—Triamcinolone—psoriasis	0.0012	0.00254	CcSEcCtD
Tiludronate—Nausea—Mycophenolic acid—psoriasis	0.0012	0.00253	CcSEcCtD
Tiludronate—Vertigo—Prednisone—psoriasis	0.00119	0.00251	CcSEcCtD
Tiludronate—Gastrointestinal pain—Hydrocortisone—psoriasis	0.00119	0.00251	CcSEcCtD
Tiludronate—Asthenia—Cyclosporine—psoriasis	0.00117	0.00248	CcSEcCtD
Tiludronate—Pain—Triamcinolone—psoriasis	0.00117	0.00247	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—STAT3—psoriasis	0.00116	0.00221	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—HLA-E—psoriasis	0.00115	0.00219	CbGpPWpGaD
Tiludronate—Abdominal pain—Hydrocortisone—psoriasis	0.00115	0.00242	CcSEcCtD
Tiludronate—Asthenia—Mycophenolate mofetil—psoriasis	0.00114	0.00241	CcSEcCtD
Tiludronate—PTPN1—Signaling Pathways—CCL20—psoriasis	0.00113	0.00214	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—CCL20—psoriasis	0.00113	0.00214	CbGpPWpGaD
Tiludronate—Musculoskeletal discomfort—Betamethasone—psoriasis	0.00113	0.00239	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.00113	0.00239	CcSEcCtD
Tiludronate—Myalgia—Prednisone—psoriasis	0.00113	0.00238	CcSEcCtD
Tiludronate—Arthralgia—Prednisone—psoriasis	0.00113	0.00238	CcSEcCtD
Tiludronate—Diarrhoea—Cyclosporine—psoriasis	0.00112	0.00236	CcSEcCtD
Tiludronate—Dyspepsia—Dexamethasone—psoriasis	0.00109	0.00231	CcSEcCtD
Tiludronate—Dyspepsia—Betamethasone—psoriasis	0.00109	0.00231	CcSEcCtD
Tiludronate—Diarrhoea—Mycophenolate mofetil—psoriasis	0.00109	0.0023	CcSEcCtD
Tiludronate—Dizziness—Cyclosporine—psoriasis	0.00108	0.00228	CcSEcCtD
Tiludronate—Back pain—Methotrexate—psoriasis	0.00107	0.00226	CcSEcCtD
Tiludronate—Pain—Dexamethasone—psoriasis	0.00106	0.00224	CcSEcCtD
Tiludronate—Pain—Betamethasone—psoriasis	0.00106	0.00224	CcSEcCtD
Tiludronate—Dizziness—Mycophenolate mofetil—psoriasis	0.00105	0.00223	CcSEcCtD
Tiludronate—Asthenia—Hydrocortisone—psoriasis	0.00104	0.0022	CcSEcCtD
Tiludronate—Headache—Cyclosporine—psoriasis	0.00102	0.00216	CcSEcCtD
Tiludronate—Gastrointestinal pain—Betamethasone—psoriasis	0.00101	0.00214	CcSEcCtD
Tiludronate—Gastrointestinal pain—Dexamethasone—psoriasis	0.00101	0.00214	CcSEcCtD
Tiludronate—Headache—Mycophenolate mofetil—psoriasis	0.000997	0.00211	CcSEcCtD
Tiludronate—Vertigo—Methotrexate—psoriasis	0.000992	0.0021	CcSEcCtD
Tiludronate—Diarrhoea—Hydrocortisone—psoriasis	0.000992	0.0021	CcSEcCtD
Tiludronate—Musculoskeletal discomfort—Prednisone—psoriasis	0.000983	0.00208	CcSEcCtD
Tiludronate—Dizziness—Prednisolone—psoriasis	0.000981	0.00208	CcSEcCtD
Tiludronate—Asthenia—Triamcinolone—psoriasis	0.000979	0.00207	CcSEcCtD
Tiludronate—Abdominal pain—Betamethasone—psoriasis	0.000979	0.00207	CcSEcCtD
Tiludronate—Abdominal pain—Dexamethasone—psoriasis	0.000979	0.00207	CcSEcCtD
Tiludronate—Nausea—Cyclosporine—psoriasis	0.000969	0.00205	CcSEcCtD
Tiludronate—PTPN1—Immune System—SOCS1—psoriasis	0.000963	0.00183	CbGpPWpGaD
Tiludronate—Dizziness—Hydrocortisone—psoriasis	0.000959	0.00203	CcSEcCtD
Tiludronate—Dyspepsia—Prednisone—psoriasis	0.000949	0.00201	CcSEcCtD
Tiludronate—Nausea—Mycophenolate mofetil—psoriasis	0.000945	0.002	CcSEcCtD
Tiludronate—Arthralgia—Methotrexate—psoriasis	0.00094	0.00199	CcSEcCtD
Tiludronate—Myalgia—Methotrexate—psoriasis	0.00094	0.00199	CcSEcCtD
Tiludronate—Headache—Prednisolone—psoriasis	0.00093	0.00197	CcSEcCtD
Tiludronate—Headache—Hydrocortisone—psoriasis	0.000908	0.00192	CcSEcCtD
Tiludronate—Dizziness—Triamcinolone—psoriasis	0.000903	0.00191	CcSEcCtD
Tiludronate—Asthenia—Dexamethasone—psoriasis	0.000889	0.00188	CcSEcCtD
Tiludronate—Asthenia—Betamethasone—psoriasis	0.000889	0.00188	CcSEcCtD
Tiludronate—Gastrointestinal pain—Prednisone—psoriasis	0.000882	0.00187	CcSEcCtD
Tiludronate—Nausea—Prednisolone—psoriasis	0.000882	0.00186	CcSEcCtD
Tiludronate—Nausea—Hydrocortisone—psoriasis	0.000861	0.00182	CcSEcCtD
Tiludronate—Headache—Triamcinolone—psoriasis	0.000855	0.00181	CcSEcCtD
Tiludronate—PTPN1—Immune System—CD8A—psoriasis	0.000854	0.00162	CbGpPWpGaD
Tiludronate—Abdominal pain—Prednisone—psoriasis	0.000853	0.0018	CcSEcCtD
Tiludronate—Diarrhoea—Dexamethasone—psoriasis	0.000847	0.00179	CcSEcCtD
Tiludronate—Diarrhoea—Betamethasone—psoriasis	0.000847	0.00179	CcSEcCtD
Tiludronate—PTPN1—Immune System—HLA-B—psoriasis	0.000821	0.00156	CbGpPWpGaD
Tiludronate—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000821	0.00174	CcSEcCtD
Tiludronate—Dizziness—Betamethasone—psoriasis	0.000819	0.00173	CcSEcCtD
Tiludronate—Dizziness—Dexamethasone—psoriasis	0.000819	0.00173	CcSEcCtD
Tiludronate—PTPN1—Cytokine Signaling in Immune system—IL6—psoriasis	0.000812	0.00154	CbGpPWpGaD
Tiludronate—Nausea—Triamcinolone—psoriasis	0.000811	0.00171	CcSEcCtD
Tiludronate—Dyspepsia—Methotrexate—psoriasis	0.000793	0.00168	CcSEcCtD
Tiludronate—Headache—Betamethasone—psoriasis	0.000776	0.00164	CcSEcCtD
Tiludronate—Headache—Dexamethasone—psoriasis	0.000776	0.00164	CcSEcCtD
Tiludronate—Asthenia—Prednisone—psoriasis	0.000774	0.00164	CcSEcCtD
Tiludronate—Pain—Methotrexate—psoriasis	0.000771	0.00163	CcSEcCtD
Tiludronate—PTPN1—Immune System—HLA-A—psoriasis	0.000761	0.00144	CbGpPWpGaD
Tiludronate—Diarrhoea—Prednisone—psoriasis	0.000738	0.00156	CcSEcCtD
Tiludronate—Gastrointestinal pain—Methotrexate—psoriasis	0.000737	0.00156	CcSEcCtD
Tiludronate—Nausea—Betamethasone—psoriasis	0.000736	0.00156	CcSEcCtD
Tiludronate—Nausea—Dexamethasone—psoriasis	0.000736	0.00156	CcSEcCtD
Tiludronate—PTPN1—Hemostasis—VEGFA—psoriasis	0.000731	0.00139	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—CRP—psoriasis	0.000726	0.00138	CbGpPWpGaD
Tiludronate—Dizziness—Prednisone—psoriasis	0.000713	0.00151	CcSEcCtD
Tiludronate—Abdominal pain—Methotrexate—psoriasis	0.000713	0.00151	CcSEcCtD
Tiludronate—ATP6V1A—Disease—HLA-A—psoriasis	0.000703	0.00133	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—HLA-DRB1—psoriasis	0.000695	0.00132	CbGpPWpGaD
Tiludronate—Headache—Prednisone—psoriasis	0.000676	0.00143	CcSEcCtD
Tiludronate—PTPN1—Immune System—ICAM1—psoriasis	0.000667	0.00127	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—NFKBIA—psoriasis	0.000662	0.00126	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—APOE—psoriasis	0.000656	0.00124	CbGpPWpGaD
Tiludronate—Asthenia—Methotrexate—psoriasis	0.000647	0.00137	CcSEcCtD
Tiludronate—Nausea—Prednisone—psoriasis	0.000641	0.00135	CcSEcCtD
Tiludronate—ATP6V1A—Signaling Pathways—SOCS1—psoriasis	0.000622	0.00118	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—SOCS1—psoriasis	0.000622	0.00118	CbGpPWpGaD
Tiludronate—Diarrhoea—Methotrexate—psoriasis	0.000617	0.0013	CcSEcCtD
Tiludronate—ATP6V1A—Disease—NOS2—psoriasis	0.000611	0.00116	CbGpPWpGaD
Tiludronate—Dizziness—Methotrexate—psoriasis	0.000596	0.00126	CcSEcCtD
Tiludronate—Headache—Methotrexate—psoriasis	0.000565	0.00119	CcSEcCtD
Tiludronate—PTPN1—Hemostasis—TP53—psoriasis	0.000553	0.00105	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—TYK2—psoriasis	0.000542	0.00103	CbGpPWpGaD
Tiludronate—Nausea—Methotrexate—psoriasis	0.000535	0.00113	CcSEcCtD
Tiludronate—PTPN1—Immune System—IFNG—psoriasis	0.000508	0.000963	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—TYK2—psoriasis	0.000501	0.00095	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—CD4—psoriasis	0.00049	0.00093	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—APOE—psoriasis	0.000459	0.000871	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—LEP—psoriasis	0.000459	0.000871	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—LEP—psoriasis	0.000459	0.000871	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—APOE—psoriasis	0.000459	0.000871	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—CD4—psoriasis	0.000453	0.000859	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—JUN—psoriasis	0.000439	0.000833	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—NFKBIA—psoriasis	0.000428	0.000812	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—NFKBIA—psoriasis	0.000428	0.000812	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—NFKB1—psoriasis	0.000422	0.000801	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—STAT3—psoriasis	0.00038	0.00072	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—TYK2—psoriasis	0.000351	0.000665	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—TYK2—psoriasis	0.000351	0.000665	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—STAT3—psoriasis	0.000351	0.000665	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—CXCL8—psoriasis	0.000305	0.000579	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—CXCL8—psoriasis	0.000305	0.000579	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—JUN—psoriasis	0.000284	0.000538	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—JUN—psoriasis	0.000284	0.000538	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—NFKB1—psoriasis	0.000273	0.000518	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—NFKB1—psoriasis	0.000273	0.000518	CbGpPWpGaD
Tiludronate—PTPN1—Immune System—IL6—psoriasis	0.000265	0.000503	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—VEGFA—psoriasis	0.000248	0.00047	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—VEGFA—psoriasis	0.000248	0.00047	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—STAT3—psoriasis	0.000245	0.000466	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—STAT3—psoriasis	0.000245	0.000466	CbGpPWpGaD
Tiludronate—ATP6V1A—Disease—IL6—psoriasis	0.000245	0.000464	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—TP53—psoriasis	0.000187	0.000355	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—TP53—psoriasis	0.000187	0.000355	CbGpPWpGaD
Tiludronate—ATP6V1A—Signaling Pathways—IL6—psoriasis	0.000171	0.000325	CbGpPWpGaD
Tiludronate—PTPN1—Signaling Pathways—IL6—psoriasis	0.000171	0.000325	CbGpPWpGaD
